Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Berger, R; Shankar, A; Fruhwald, F; Fahrleitner-Pammer, A; Freemantle, N; Tavazzi, L; Cleland, JG; Pacher, R.
Relationships between cardiac resynchronization therapy and N-terminal pro-brain natriuretic peptide in patients with heart failure and markers of cardiac dyssynchrony: an analysis from the Cardiac Resynchronization in Heart Failure (CARE-HF) study.
Eur Heart J. 2009; 30(17): 2109-2116.
Doi: 10.1093/eurheartj/ehp210
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Fahrleitner-Pammer Astrid
- Fruhwald Friedrich
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- AIMS: The Cardiac Resynchronization in Heart Failure (CARE-HF) study showed that cardiac resynchronization therapy (CRT) reduces mortality in HF patients with markers of dyssynchrony. Plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) might predict which patients benefit most from CRT. We evaluated whether the prognostic value of NT-proBNP was influenced by CRT and the effects of CRT stratified according to NT-proBNP. METHODS AND RESULTS: A total of 813 patients were enrolled in CARE-HF. Baseline log-transformed NT-proBNP independently predicted all-cause mortality, sudden death, and death from pump failure. In a multivariable model including log-transformed NT-proBNP, assignment to CRT remained independently associated with better prognosis without evidence of interaction. Stratifying patients according to the median NT-proBNP and to CRT treatment allocation, all-cause mortality was 12% if
or= median + CRT, and 51% if >or= median + control group. There was no evidence of a difference in the relative effect of CRT across different values of NT-proBNP. Conclusion: NT-proBNP retains its prognostic value in HF patients with CRT. Deploying CRT before the patients have reached end-stage HF may maximize the benefit of treatment. - Find related publications in this database (using NLM MeSH Indexing)
- Adrenergic beta-Antagonists - therapeutic use
- Aged -
- Angiotensin-Converting Enzyme Inhibitors - therapeutic use
- Arrhythmias, Cardiac - blood
- Biological Markers - metabolism
- Cardiac Pacing, Artificial -
- Diuretics - therapeutic use
- Female -
- Heart Failure - blood
- Humans -
- Kaplan-Meier Estimate -
- Male -
- Middle Aged -
- Natriuretic Peptide, Brain - metabolism
- Peptide Fragments - metabolism
- Spironolactone - therapeutic use
- Treatment Outcome -
- Ventricular Dysfunction, Left - therapy
- Find related publications in this database (Keywords)
- Heart failure
- Cardiac resynchronization therapy
- Natriuretic peptides
- Prognosis